PolarityTE announced that patient enrollment has begun for two new randomized controlled trials evaluating SkinTE for the treatment of chronic wounds, specifically diabetic foot ulcers and venous leg ulcers. SkinTE is commercially available through a regional market release and is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.